Siemens Fonds Invest’s Alnylam Pharmaceuticals ALNY Stock Holding History

Siemens Fonds Invest’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$879K	Buy	2,919 +81	+3%	+$24.4K	0.04%	272
2026 Q1	$939K	Buy	2,838 +1,001	+54%	+$341K	0.05%	245
2025 Q4	$730K	Hold	1,837	–	–	0.04%	280
2025 Q3	$838K	Sell	1,837 -6	-0.3%	-$2.44K	0.05%	252
2025 Q2	$601K	Buy	1,843 +372	+25%	+$103K	0.04%	289
2025 Q1	$397K	Buy	1,471 +106	+8%	+$27.2K	0.03%	314
2024 Q4	$322K	Hold	1,365	–	–	0.02%	368
2024 Q3	$375K	Buy	+1,365	New	+$355K	0.03%	318

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Siemens Fonds Invest's ALNY Position: Q2 2026 in Review

Siemens Fonds Invest increased its Alnylam Pharmaceuticals (ALNY) stake by 2.9% in Q2 2026, buying an estimated $24.4K and bringing the position to 2,919 shares worth $879K. The position accounts for 0.04% of the portfolio, ranked #272.

Siemens Fonds Invest first reported a position in ALNY in Q3 2024 and has held it in 8 quarters since. The position peaked at $939K in Q1 2026. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Siemens Fonds Invest held 2,919 shares of Alnylam Pharmaceuticals worth $879K as of Q2 2026.
Siemens Fonds Invest bought 81 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $24.4K.
Alnylam Pharmaceuticals made up 0.04% of Siemens Fonds Invest's portfolio in Q2 2026, its #272 holding.
Siemens Fonds Invest first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
Siemens Fonds Invest's Alnylam Pharmaceuticals position peaked at $939K in Q1 2026.
793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Siemens Fonds Invest's 13F filing for Q2 2026, filed 14 Aug 2026.